# Study to Assess the Safety and Efficacy of SelK2 to Prevent Blood Clots in Patients Undergoing Total Knee Replacement

Study · id `cardio:ct-nct03812328` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03812328](<https://clinicaltrials.gov/study/NCT03812328>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03812328

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 207 participants.

## Technical summary

Registry record NCT03812328. Randomized; single masking; primary purpose prevention. Start 2019-02-20 (actual); primary completion 2019-10-01 (actual). Results posted on 2020-11-24.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose prevention
- Phase: Phase 2
- Enrolled: 207 participants (enrolled count; ClinicalTrials.gov record NCT03812328, source copy `cardio:ctgov-nct03812328-2021-01-06`, retrieved 2026-10-31)
- Started: 2019-02-20 (actual) (ClinicalTrials.gov record NCT03812328, source copy `cardio:ctgov-nct03812328-2021-01-06`, retrieved 2026-10-31)
- Primary completion: 2019-10-01 (actual) (ClinicalTrials.gov record NCT03812328, source copy `cardio:ctgov-nct03812328-2021-01-06`, retrieved 2026-10-31)
- Completion: 2019-11-14 (actual) (ClinicalTrials.gov record NCT03812328, source copy `cardio:ctgov-nct03812328-2021-01-06`, retrieved 2026-10-31)
- Results first posted: 2020-11-24 (ClinicalTrials.gov record NCT03812328, source copy `cardio:ctgov-nct03812328-2021-01-06`, retrieved 2026-10-31)
- Countries: Bulgaria; Latvia; Lithuania; Poland; Ukraine (ClinicalTrials.gov record NCT03812328, source copy `cardio:ctgov-nct03812328-2021-01-06`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03812328-2021-01-06`, retrieved 2026-10-31)

## The registry's words

- Brief title: Study to Assess the Safety and Efficacy of SelK2 to Prevent Blood Clots in Patients Undergoing Total Knee Replacement
- Acronym: COURSE
- Condition: Venous Thromboembolism
- Intervention (Drug): SelK2
- Intervention (Biological): Enoxaparin
- Lead sponsor: Tetherex Pharmaceuticals Corporation
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Deep vein thrombosis (`cardio:deep-vein-thrombosis`)
- Registry intervention name matches this record: Enoxaparin (`core:enoxaparin`)

## Provenance

Content hash: 7c173624a16f7917515f21ef6c64cda432112ca7be48194de6969f0a9218ab9a
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
